Skip to content

Author

M. Albayyaa

We have 3 of 31 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Cardiovascular and Kidney Outcomes of Tirzepatide versus Semaglutide in Stage 2 Cardiovascular-Kidney-Metabolic Syndrome: A Propensity Score-matched Cohort Study

Cardiovascular-kidney-metabolic (CKM) syndrome describes the overlapping burden of metabolic dysfunction, chronic kidney disease, and cardiovascular disease. Tirzepatide and semaglutide are both recommended for patients with type 2 diabetes and obesity, yet no randomized trial has directly compared their effect on...

A. Qadeer, M. Khalid, D. Leblanc et al. · 0 citations
Review Open access Sep 2026

The PREVENT Equations Evidence Appraisal of Validation and Clinical Implications.

The American Heart Association's PREVENT equations offer a contemporary, race-free alternative to the Pooled Cohort Equations (PCE), incorporating kidney function to estimate 10- and 30-year risks of atherosclerotic cardiovascular disease (ASCVD), heart failure, and total CVD. PREVENT-ASCVD is now recommended for prima...

I. Mortada, Ebrahim Adel Elkolaly, Aaron W. Lee et al. · 0 citations
Jul 2026

Secondary Atrial Fibrillation in Critically Ill Sepsis Patients: Evaluating the Role of Early Oral Anticoagulants in a Retrospective Multi-Center Study.

In sepsis-associated NOAF, early OAC initiation was associated with reduced short-term mortality and ischemic stroke without excess bleeding or thromboembolic risk and warrant cautious interpretation given the observational design.

A. Qadeer, Michele Fouad, Doaa Bayomi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.